48 Followers on Owler

Lodo Therapeutics

Read more
Dale R. Pfost's photo - Chairman & CEO of Lodo Therapeutics

Chairman & CEO

Dale R. Pfost

CEO Approval Rating

89/100

Founded:

2015

Status:

LODO THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Dale R. Pfost

Chairman & CEO

- -
134
$17M
$12M
View Profile
1

Abbie Celniker

Interim-CEO

90/100
20
$82M
$ < 1M
View Profile
2

Michael Bruce

CEO

90/100
20
$25M
$1.4M
View Profile
3

Ying Luo

Chairman & CEO

85/100
40
$81M
$5.6M
View Profile
4

Roberto Iacone

CEO

90/100
8
$79.2M
$1.4M
View Profile
5

Meenu Chhabra

President & CEO

64/100
44
$162.6M
$5M
View Profile
6

Mike Westby

CEO

67/100
19
$5.8M
$3.5M
View Profile
7

J Scott Wolchko

President & CEO

75/100
104
$366.3M
$40.1M
View Profile
8

Andrey Kolokoltsov

CEO

- -
20
$43M
$5M
View Profile
9

Harlan W. Waksal

President & CEO

61/100
116
$98.5M
$2.1M
View Profile
10

Paul Boucher

President & CEO

85/100
32
$3M
$4.1M
View Profile

Missing a competitor? Contribute!

Flare Therapeutics is one of Lodo Therapeutics's top competitors. Flare Therapeutics was founded in 2021 in Cambridge, Massachusetts. Like Lodo Therapeutics, Flare Therapeutics also operates in the Biotechnology industry. Flare Therapeutics generates $11.5M less revenue than Lodo Therapeutics.

Exo Therapeutics is a top competitor of Lodo Therapeutics. Exo Therapeutics was founded in 2018, and is headquartered in Cambridge, Massachusetts. Like Lodo Therapeutics, Exo Therapeutics also competes in the Biotechnology field. Exo Therapeutics generates $10.6M less revenue vs. Lodo Therapeutics.

Cullgen is seen as one of Lodo Therapeutics's top competitors. Cullgen is headquartered in San Diego, California, and was founded in 2018. Like Lodo Therapeutics, Cullgen also operates in the Biotechnology field. Cullgen generates 46% the revenue of Lodo Therapeutics.

Lodo Therapeutics Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Hibiskus Biopharma, Inc.

Sep 2020

Source »
undisclosed
Hibiskus is a biotechnology company that develops and commercializes novel small-molecule therapeutics for the treatment of cancer.

These are all the companies that Lodo Therapeutics has acquired. Lodo Therapeutics' latest acquisition was Hibiskus Biopharma, Inc. in Sep 2020. Hibiskus is a biotechnology company that develops and commercializes novel small-molecule therapeutics for the treatment of cancer.

Lodo Therapeutics Funding History

Since Lodo Therapeutics was founded in 2015, it has participated in 1 round of funding. In total Lodo Therapeutics has raised $17.0M. Lodo Therapeutics' funding round was on Jan 2016 for a total of $17.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series A
Jan 2016
$17M

Since Lodo Therapeutics was founded in 2015, it has participated in 1 round of funding. In total Lodo Therapeutics has raised $17.0M. Lodo Therapeutics' funding round was on Jan 2016 for a total of $17.0M

Lodo Therapeutics Investments

No recent investments found related to Lodo Therapeutics

Lodo Therapeutics News

August 7, 2020BioSpace

Lodo Therapeutics Acquires Conifer Point Pharmaceuticals

--Expands AI/ML Capabilities and Gains Exclusive Rights to Leading Suite of Cheminformatics Technolog... See more »
April 7, 2020BioSpace

Lodo Therapeutics Achieves Preclinical Milestone In Strategic Collaboration with Genentech

Lodo Therapeutics Corp., a biotechnology company applying its proprietary platform to reinvent natura... See more »
August 15, 2018Pharamceutical Technology

Genentech and Lodo launch $1bn project to develop new drugs from earth

Scientists have been digging deep in the dirt microbiome for decades in search of potential new drug ... See more »
May 10, 2018PharmaLeaders

Genentech, Lodo Therapeutics form $969m drug discovery collaboration

Published 10 May 2018 Roche's subsidiary Genentech has entered into a strategic drug discovery collab... See more »
December 24, 2015www.sec.gov

Received $3.5M in Equity Funding

Social Media

Lodo Therapeutics Headquarters

430 E 29th St. Suite 625

New York, New York10016

1-646-828-5950

Driving Directions »

Trending Companies

Lodo Therapeutics Summary

ABOUT

Overview

Lodo Therapeutics is a New York-based biotechnology firm that discovers and develops novel therapeutics for the treatment of patients with cancer. Lodo Therapeutics was founded in 2015. Lodo Therapeutics' headquarters is located in New York, New York,...

CEO

Lodo Therapeutics's Chairman & CEO, Dale R. Pfost, currently has an approval rating of 89%. Lodo Therapeutics's primary competitors are Flare Therapeutics, Exo Therapeutics & Cullgen.

Frequently Asked Questions about Lodo Therapeutics

  1. When was Lodo Therapeutics founded?

    Lodo Therapeutics was founded in 2015
  2. Who is Lodo Therapeutics's CEO?

    Lodo Therapeutics's CEO is Dale R. Pfost
  3. How much revenue does Lodo Therapeutics generate?

    Lodo Therapeutics generates $12M in revenue
  4. How much funding does Lodo Therapeutics have?

    Lodo Therapeutics has historically raised $17M in funding
  1. Where is Lodo Therapeutics's headquarters?

    Lodo Therapeutics's headquarters is in New York New York, USA
  2. How many employees does Lodo Therapeutics have?

    Lodo Therapeutics has 134 employees
  3. What sector does Lodo Therapeutics operate in?

    Lodo Therapeutics is in Biotechnology
  4. Who are Lodo Therapeutics's competitors?

    Lodo Therapeutics's top competitors are Flare Therapeutics, Exo Therapeutics, Cullgen